Orient Pharma Valuation

Is 4166 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4166 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4166 (NT$38.95) is trading above our estimate of fair value (NT$22.04)

Significantly Below Fair Value: 4166 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4166?

Key metric: As 4166 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 4166. This is calculated by dividing 4166's market cap by their current earnings.
What is 4166's PE Ratio?
PE Ratio	72.9x
Earnings	NT$119.10m
Market Cap	NT$8.69b

4166 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	8.6x
Enterprise Value/EBITDA	35.3x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 4166's PE Ratio compare to its peers?

The above table shows the PE ratio for 4166 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	40.7x
1271 SunWay Biotech	51.6x	n/a	NT$5.1b
4746 Formosa Laboratories	24.1x	n/a	NT$9.5b
4119 SCI Pharmtech	24.2x	n/a	NT$11.7b
1760 Panion & Bf Biotech	63.1x	n/a	NT$7.7b
4166 Orient Pharma	72.9x	n/a	NT$8.7b

Price-To-Earnings vs Peers: 4166 is expensive based on its Price-To-Earnings Ratio (72.9x) compared to the peer average (40.7x).

Price to Earnings Ratio vs Industry

How does 4166's PE Ratio compare vs other companies in the TW Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 4166 is expensive based on its Price-To-Earnings Ratio (72.9x) compared to the TW Pharmaceuticals industry average (23x).

Price to Earnings Ratio vs Fair Ratio

What is 4166's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4166 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	72.9x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 4166's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

YungShin Global Holding

NT$15.5b

Through its subsidiaries, invests in, manufactures, and sells medicines, animal drugs, agricultural chemicals, industrial medicines, and cosmetics in Taiwan, Mainland China, Japan, and the United States.

3705

NT$58.10

8.6%

27.7%

RBC Bioscience

NT$258.9m

Researches, develops, manufactures, and sells reagents and devices for life science and molecular diagnosis in Europe, the United States, Asia, Taiwan, Africa, and Australia.

6848

NT$19.95

-0.7%

32.1%

Cenra

NT$6.0b

Engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for humans and animals.

1701

NT$21.15

-8.8%